The authors hypothesized that pemafibrate would reduce liver enzymes and hepatic steatosis or fibrosis to the same extent as an intensive lifestyle Intervention (ILI) to induce 3 %‒5 % weight loss, and that pemafibrate reduces the serum sDPP-4/CD26 level in association with liver enzymes in people with type 2 diabetes and MASLD. The gene discussed is DPP4; the disease is Hepatic steatosis.